2024 Poster Award Recipients

AMCP Foundation 2024 Best Poster Competition Recipients

AMCP Foundation and Artia Solutions proudly recognize the Nexus 2024 Best Poster Award recipients. The Competition hosted authors presenting cutting-edge research, and Best Poster judges evaluated their research based on scientific merit, evidence of innovation and practicality, strength and clarity of conclusions, and visual interpretation of data.

Best Poster Virtual Presentation Now Available Online!

Nexus 2024: Best Poster Recipients supported by Artia Solutions

	Best Student Pharmacist Poster: Lokhay Shelby Chan, PharmD/MBA Candidate 2025, University at Buffalo School of Pharmacy and Pharmaceutical Sciences: "A Cost-Benefit Analysis of a Social Determinants of Health Program within a Clinical Integrated Network of Community Pharmacies"
	Best Resident/Fellow Poster: Amy Wu, University of North Carolina Eshelman School of Pharmacy: "The Economic Burden of COVID-19 Vaccine Hesitancy: A Systematic Literature Review"
	Best Graduate Student Poster: Minal Walvekar, Master of Data Science Candidate: "Comparison of Change in Cardiac Injury Marker in Glucagon-Like Peptide-1 Receptor Agonist, Sodium-Glucose Cotransporter-2 Inhibitor, and Dipeptidyl Peptidase IV Inhibitor Users in a RealWorld Database"

AMCP 2024: Best Poster Competition Recipients supported by CVS Health

	Best Student Pharmacist Poster: Ailsa Watson, PharmD and MMHC Candidate 2025, Lipscomb University, College of Pharmacy: “Assessment of the Implementation of Collaborative Pharmacy Practice Agreements in an Integrated Health System Specialty Pharmacy."
	Best Resident/Fellow Poster: Ai Quynh Nguyen, PharmD, Magellan Rx Management, a Prime Therapeutics Company: “Retrospective Claims Analysis of Opioid-Prescribing Patterns: Single and Combination Agents for Acute Pain and Subsequent Conversation to Chronic Opioid Usage Among Commercial Patients."
	Best Graduate Student Poster: Sun Choi, PharmD, University of Illinois at Chicago, College of Pharmacy: “Healthcare Costs Among Patients with Myasthenia Gravis in the United States."